BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38724349)

  • 1. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.
    Heesterman BL; Aben KKH; van den Bergh ACM; van der Voort van Zyp JRN; Bokhorst LP
    Urol Oncol; 2024 May; ():. PubMed ID: 38724349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone.
    Andruska N; Fischer-Valuck BW; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Michalski JM; Baumann BC
    J Natl Compr Canc Netw; 2022 Feb; 20(4):343-350.e4. PubMed ID: 35193114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
    Patel SA; Ma TM; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; DeWeese TL; Tilki D; Ciezki JP; Karnes RJ; Nickols NG; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Boutros PC; Romero T; Horwitz EM; Tendulkar RD; Steinberg ML; Spratt DE; Xiang M; Kishan AU
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):645-653. PubMed ID: 36179990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial.
    Reitblat C; Fleishman A; Kaplan IA; Stensland KD; D'Amico AV; Olumi AF; Wagner AA; Chang PK; Kim SP; Korets R; Gershman B
    Urol Oncol; 2021 Nov; 39(11):785.e1-785.e10. PubMed ID: 33934965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
    Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
    JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
    Schmidt-Hegemann NS; Zamboglou C; Mason M; Mottet N; Hinnen K; De Meerleer G; Cozzarini C; Maingon P; Henry A; Spahn M; Cornford P; Belka C; Wiegel T
    Radiother Oncol; 2023 Jun; 183():109544. PubMed ID: 36813168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
    Sargos P; Mottet N; Bellera C; Richaud P
    BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
    Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
    Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Kishan AU; Shaikh T; Wang PC; Reiter RE; Said J; Raghavan G; Nickols NG; Aronson WJ; Sadeghi A; Kamrava M; Demanes DJ; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    Eur Urol; 2017 May; 71(5):766-773. PubMed ID: 27452951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
    Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
    Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CLINICAL OUTCOMES OF EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH NEOADJUVANT ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK PROSTATE CANCER].
    Okada T; Takayama K; Kokubo M; Kono Y; Matsumoto K; Sumiyoshi T; Masuda N; Shiraishi Y; Negoro H; Utsunomiya N; Tsunemori H; Okubo K; Segawa T; Moroi S; Muguruma K; Kawakita M
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(3):162-169. PubMed ID: 28740047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
    Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
    Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
    Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE
    J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
    Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.